Abstract 348P
Background
Malignant melanoma is an extremely rare malignancy in the Indian subcontinent and South east Asia. Its already known that Asian countries have different clinical presentation of melanoma. It would be interesting to know the epidemiology and outcome of advanced disease in Indian patients.
Methods
We retrospectively analysed patients with malignant melanoma who were registered in Medical Oncology clinic at AIIMS, New Delhi between January 2016 and July 2019. We used SPSS version 23 for analysis. Immunotherapy used was single agent Nivolumab as Ipilimumab is unavailable.
Results
Total of 93 patients (57 males, 36 females) were registered in the study. Median age was 53 (range, 25 to 85 years), with the commonest primary sites being anorectal (n = 23) and foot (n = 23), followed by eye (n = 15), head and neck (n = 12), thigh (n = 9), others (n = 11) respectively. The commonest sites of metastasis were lymph nodes (n = 54, 58.1%), lung (n = 45,48.4%), liver(n = 33,35.5%) and bone(n = 25,26.9%).The median sites of metastasis was two (range 1-5). Most patients had ECOG PS 1-2 (n = 77, 82.8%). Majority of the patients (n = 80,86%) had metastasis.Out of 93 patients, 39(42%) received chemotherapy in first line, 16 (17.3%) received Immunotherapy, 13 (13.9%) underwent surgery and best supportive care was offered to 25 (26.8%) patients. The chemotherapy used were dacarbazine (n = 27), nabpaclitaxel (n = 6) and others (n = 6). Among patients who received chemo, median number of cycles was 5 (range,1-15) and response assessment revealed progressive disease in 17 patients, stable disease in 4 patients, partial response in one patient, and remaining 16 patients defaulted and were not evaluable. Among patients who received Single agent Nivolumab, the median number of cycles was 5 (range,2-15) and response showed progressive disease in all patients, except one. Median follow up was 18 months and median PFS was 3 months.
Conclusions
This study shows that the site of melanoma in Indian patients is different as compared to western patients with higher number of anorectal, mucosal and acral melanoma. Immunotherapy was feasible for only a fraction of patients in view of exorbitant cost. Non availability of BRAF therapies and Ipilimumab is of great concern in view of poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract